
Kardigan develops personalized cardiovascular medicines intended to move patients beyond symptom management toward functional cures. The company uses a proprietary Cardiac Intelligence R&D platform and AI-based analytics to identify biomarkers for safety, efficacy, and patient responder selection prior to human trials. Kardigan is a clinical-stage biopharmaceutical company that integrates biomarker-driven patient selection and data-driven trial design into its development programs. The company is building a portfolio of therapies that target underlying cardiovascular disease pathophysiology to address unmet needs in heart health.

Kardigan develops personalized cardiovascular medicines intended to move patients beyond symptom management toward functional cures. The company uses a proprietary Cardiac Intelligence R&D platform and AI-based analytics to identify biomarkers for safety, efficacy, and patient responder selection prior to human trials. Kardigan is a clinical-stage biopharmaceutical company that integrates biomarker-driven patient selection and data-driven trial design into its development programs. The company is building a portfolio of therapies that target underlying cardiovascular disease pathophysiology to address unmet needs in heart health.
About Us Kardigan is a heart health company working to make cardiovascular disease preventable, curable and no longer the leading cause of death in the world.
It is Kardigan’s mission to develop multiple targeted treatments in parallel that bring people with cardiovascular diseases to the cures they deserve.
Led by Tassos Giannakakos, Jay Edelberg, M.D. and Bob McDowell, Ph.D., Kardigan’s co-founders have reunited after leading MyoKardia to discover and develop mavacamten, the first cardiac myosin inhibitor, resulting in an acquisition by Bristol Myers Squibb in 2020.
We have a cutting-edge discovery and translational research platform, a pipeline of late-stage candidates, and an industry-leading team that is driven to improve the lives of patients.
At Kardigan, we are motivated by our values which guide how we work, interact, and achieve our goals. , we are deeply committed to improving the lives of patients and prioritizing their needs above all else. We believe in —leading with truth to bring out the best in others by creating an environment where every person knows they will be fully accepted. With an , we encourage the highest levels of curiosity and are open to changing our minds. We are committed to with urgency, excellence, and intention, and support each other no matter what role we play or where we sit. Lastly, we strive to because patients are counting on us. We are not afraid to take risks to unlock innovation and advance scientific discoveries.
These values are the foundation of our work, empowering us to make a real difference, every day.
Role Summary The Head of Development Services is responsible for building and overseeing the operational backbone that enables efficient, compliant, and scalable clinical development. The role leads centralized development services—including Business Operations, Trial Master File (TMF) Management, and Vendor Relationship & Management—ensuring consistency, transparency, and quality across the development portfolio. The role is a member of the Development Operations & Biometrics leadership team, and as such, participates in senior leadership meetings and strategic initiatives across the development organization.
Key Responsibilities
Qualifications & Preferred Skills
Or advanced degree (PhD, MBA, Masters) and 12+ yrs of experience